博士伦
BLCO
16.49
-0.17
-1.02%
博士伦
US · BLCO
#1909 按市值排名
上市于 2022
16.49
-0.17
-1.02%
实时 - 追踪5344个代码 - 心跳于530秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了2家。
- 机构持股总比例下降了2.1个百分点。
机构持股
- 机构持股比例
- 97.37% -2.08pp
- 机构数量
- 110 -2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Public Company88.32%
Hedge Fund4.72%
Mutual Fund1.74%
Family Office/Trust1.23%
VC/PE Fund1.12%
Individual/Insider0.33%
Private Company0.22%
Other2.30%
主要股东 截至 2025-12-09
Bausch Health Companies Inc.
86.92% · 310.45M 股
Icahn Capital LP
0.98% · 3.50M 股
Brookfield Corporation
0.96% · 3.44M 股
Deutsche Bank Aktiengesellschaft
0.96% · 3.42M 股
D. E. Shaw & Co., L.P.
0.93% · 3.32M 股
Davidson Kempner Capital Management LP
0.88% · 3.16M 股
GoldenTree Asset Management LP
0.74% · 2.66M 股
T. Rowe Price Group, Inc.
0.61% · 2.16M 股
Glenview Capital Management, LLC
0.54% · 1.92M 股
Arrowstreet Capital, Limited Partnership
0.38% · 1.36M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 34次买入 · 15次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Bausch Health Companies Inc. | -- | 86.92% |
| Brenton Saunders | Chairperson & CEO | 0.12% |
| Osama Eldessouky | Chief Financial Officer | 0.06% |
| Yehia Hashad | Executive VP of Research & Development and Chief Medical officer | 0.05% |
| A. Robert Bailey | Chief Legal Officer | 0.04% |
| Andrew von Eschenbach | Independent Director | 0.01% |
| Luc Bonnefoy | President of Surgical | 0.01% |
| Richard De Schutter | Independent Director | 0.01% |
| Andrew Stewart | President of Global Pharmaceuticals & International Consumer | 0.01% |
| Thomas Appio | Director | 0.01% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-27 | Karen Ling | Director | Intent to Sell (Form 144) | -4,500 | $16.83 |
| 2026-08-11 | Laurence Paul | Director | Other Acquisition | +11,776 | -- |
| 2026-08-11 | Robert Chersi | Director | Other Acquisition | +11,776 | -- |
| 2026-08-11 | Barbara Trebbi | Director | Other Acquisition | +11,776 | -- |
| 2026-08-09 | Frederick Munsch | Chief Accounting Officer | Open Market Disposition | -52,900 | $16.78 |
| 2026-08-09 | Frederick Munsch | Chief Accounting Officer | Intent to Sell (Form 144) | -52,900 | $16.78 |
| 2026-08-06 | Andrew von Eschenbach | Independent Director | Open Market Disposition | -18,559 | $16.50–16.58 |
| 2026-08-06 | Andrew von Eschenbach | Independent Director | Intent to Sell (Form 144) | -6,059 | $16.58 |
| 2026-08-05 | Andrew von Eschenbach | Independent Director | Intent to Sell (Form 144) | -12,500 | $16.50 |
| 2026-08-04 | Brenton Saunders | Chairperson & CEO | Sale to Issuer | -4,231 | $16.76 |
| 2026-08-04 | Brenton Saunders | Chairperson & CEO | Other Acquisition | +281,879 | -- |
| 2026-08-04 | Thomas Appio | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-08-04 | A. Robert Bailey | Chief Legal Officer | Other Acquisition | +33,557 | -- |
| 2026-08-04 | Osama Eldessouky | Chief Financial Officer | Other Acquisition | +50,335 | -- |
| 2026-08-04 | Yehia Hashad | Executive VP of Research & Development and Chief Medical officer | Other Acquisition | +20,973 | -- |
| 2026-08-04 | Frederick Munsch | Chief Accounting Officer | Other Acquisition | +9,091 | -- |
| 2026-08-04 | Andrew Stewart | President of Global Pharmaceuticals & International Consumer | Other Acquisition | +16,778 | -- |
| 2026-08-04 | Luc Bonnefoy | President of Surgical | Other Acquisition | +16,778 | -- |
| 2026-06-11 | Luc Bonnefoy | President of Surgical | Sale to Issuer | -1,008 | $15.08 |
| 2026-05-25 | Steven Collis | Director | Other Acquisition | +15,842 | $15.78 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
博士伦 讨论区 0 条评论